A framework for applying the precautionary principle to transfusion safety

Transfusion Medicine Reviews

Volumn 25, Issue 3, 2011, Pages 177-183

  Wilson, Kumanan ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD; BLOOD SAFETY; BLOOD TRANSFUSION; CLINICAL DECISION MAKING; CLINICAL PROTOCOL; CONCEPTUAL FRAMEWORK; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; EVIDENCE BASED MEDICINE; HEALTH CARE POLICY; HUMAN; MEDICAL TECHNOLOGY; PATIENT CARE; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECIPIENT; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; STANDARD; TRANSFUSION SAFETY; VIRUS TRANSMISSION;

ALGORITHMS; BLOOD SAFETY; BLOOD TRANSFUSION; CONCEPT FORMATION; DECISION MAKING; EVIDENCE-BASED MEDICINE; HUMANS; PRACTICE GUIDELINES AS TOPIC; PREVENTIVE MEDICINE;

EID: 79958859778     PISSN: 08877963     EISSN: 15329496     Source Type: Journal    
DOI: 10.1016/j.tmrv.2011.01.004     Document Type: Review

References (46)

1. Wilson K., Ricketts M.N. The success of precaution? Managing the risk of transfusion transmission of variant Creutzfeldt-Jakob disease. Transfusion 2004, 44:1475-1478.
2. Kriebel D., Tickner J. Reenergizing public health through precaution. Am J Public Health 2001, 91:1351-1355.
3. Vamvakas E.C. Evidence-based practice of transfusion medicine: Is it possible and what do the words mean?. Transfus Med Rev 2004, 18:267-278.
4. Sackett D.L., Rosenberg W.M., Gray J.A., et al. Evidence based medicine: What it is and what it isn't. BMJ 1996, 312:71-72.
5. Upshur R.E. Are all evidence-based practices alike? Problems in the ranking of evidence. CMAJ 2003, 169:672-673.
6. National Forum on Health Canada Health Action: Building on the Legacy-Volume I-The final report 1997, Health Canada, Ottawa, Canada. http://www.hc-sc.gc.ca/hcs-sss/pubs/renewal-renouv/1997-nfoh-fnss-v1/index-eng.php#a3.
7. Aach R.D., Szmuness W., Mosley J.W., et al. Serum alanine aminotransferase of donors in relation to the risk of non-A,non-B hepatitis in recipients: The transfusion-transmitted viruses study. N Engl J Med 1981, 304:989-994.
8. Alter H.J., Purcell R.H., Holland P.V., et al. Donor transaminase and recipient hepatitis. Impact on blood transfusion services. JAMA 1981, 246:630-634.
9. Krever H. Canada's rejection of surrogate testing. Commission of Inquiry on the Blood System in Canada. Final Report. Vol. Chapter 24 1997, 649-686. Canadian Government Publishing, Ottawa.
10. Blajchman M.A., Bull S.B., Feinman S.V. Post-transfusion hepatitis: Impact of non-A, non-B hepatitis surrogate tests. Canadian Post-Transfusion Hepatitis Prevention Study Group. Lancet 1995, 345:21-25.
11. Wilson K., Graham I., Ricketts M., et al. Variant Creutzfeldt-Jakob disease and the Canadian blood system after the tainted blood tragedy. Soc Sci Med 2007, 64:174-185.
12. Wilson K., Hebert P.C., Laupacis A., et al. A policy analysis of major decisions relating to Creutzfeldt-Jakob disease and the blood supply. CMAJ 2001, 165:59-65.
13. Wilson K. Risk, causation and precaution. Public health law &policy in Canada 2005, Vol. 3:59-87. LexisNexis Butterworths, Markham, ON. T. Bailey, T. Caulfield, N. Ries (Eds.).
14. Foster K.R., Vecchia P., Repacholi M.H. Risk management. Science and the precautionary principle. Science 2000, 288:979-981.
15. United Nations.(United Nations) 1992.
16. European Community. Treaty Establishing the European Community, Feb 7, 1992, reprinted in 31 ILM 247 art 130r(2) (1992).
17. Wingspread conference participants 1998.
18. VanderZwaag D. The precautionary principle in environmental law and policy: Elusive rhetoric and first embraces. J Environ Law Pract 1999, 8:355-375.
19. Goldstein B.D., Carruth R.S. Implications of the precautionary principle: Is it a threat to science?. Int J Occup Med Environ Health 2004, 17:153-161.
20. Morris J. Defining the precautionary principle. Rethinking risk and the Precautionary Principle 2000, 1-21. Butterworth-Heinemann, Oxford. J. Morris (Ed.).
21. Goklany I.M. From precautionary principle to risk-risk analysis. Nat Biotechnol 2002, 20:1075.
22. Wilson K., Wilson M., Hebert P.C., et al. The application of the precautionary principle to the blood system: The Canadian blood system's vCJD donor deferral policy. Transfus Med Rev 2003, 17:89-94.
23. Attaran A., Maharaj R. Ethical debate: Doctoring malaria, badly: The global campaign to ban DDT. BMJ 2000, 321:1403-1405.
24. BBC News Famine-hit Zambia rejects GM food aid. 29 October, 2002 http://news.bbc.co.uk/2/hi/africa/2371675.stm.
25. Krever H. Commission of Inquiry on the Blood System in Canada. Final Report 1997, Canadian Government Publishing, Ottawa, Canada.
26. Cashman NR: New variant Creutzfeldt-Jakob disease and the Canadian blood supply: Scientific basis of risk. Report for Laboratory Centre for Disease Control, January 15, 1999.
27. Wroe S.J., Pal S., Siddique D., et al. Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: A case report. Lancet 2006, 368:2061-2067.
28. Llewelyn C.A., Hewitt P.E., Knight R.S., et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004, 363:417-421.
29. Hewitt P.E., Llewelyn C.A., Mackenzie J., et al. Creutzfeldt-Jakob disease and blood transfusion: Results of the UK Transfusion Medicine Epidemiological Review study. Vox Sang 2006, 91:221-230.
30. Wilson K., Ricketts M.N. Transfusion transmission of vCJD: A crisis avoided?. Lancet 2004, 364:477-479.
31. News CBC. Blood agency takes precautions against SARS. 2003 Apr 11.
32. Pealer L.N., Marfin A.A., Petersen L.R., et al. Transmission of West Nile virus through blood transfusion in the United States in 2002. N Engl J Med 2003, 349:1236-1245.
33. Vamvakas E.C., Kleinman S., Hume H., et al. The development of West Nile virus safety policies by Canadian blood services: Guiding principles and a comparison between Canada and the United States. Transfus Med Rev 2006, 20:97-109.
34. Wilson K. The Krever Commission-10 years later. CMAJ 2007, 177:1387-1389.
35. Laupacis A., Feeny D., Detsky A.S., et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992, 146:473-481.
36. AuBuchon J., Petz L. Making decisions to improve transfusion safety. Policy alternatives in transfusion medicine 2001, 184-226. AABB Press, Bethesda (Md). J. AuBuchon, L. Petz, A. Fink (Eds.).
37. van Hulst M., de Wolf J.T., Staginnus U., et al. Pharmaco-economics of blood transfusion safety: review of the available evidence. Vox Sang 2002, 83:146-155.
38. Custer B., Hoch J.S. Cost-effectiveness analysis: What it really means for transfusion medicine decision making. Transfus Med Rev 2009, 23:1-12.
39. Commission of the European Communities Communication from the commission on the Precautionary Principle COM(2000) 1 (Brussels: 2 February 2000). http://ec.europa.eu/dgs/health_consumer/library/pub/pub07_en.pdf.2000.
40. Canada Gazette Part II - Order Adding a Toxic Substance to Schedule 1 to the Canadian Environmental Protection Act, 1999 - SOR/2010-194. Vol. 144 No. 21. October 13 2010 (at 1806-1818) Available:. http://www.gazette.gc.ca/rp-pr/p2/2010/2010-10-13/pdf/g2-14421.pdf.
41. vom Saal F.S., Myers J.P. Bisphenol A and risk of metabolic disorders. JAMA 2008, 300:1353-1355.
42. United Nations Environment Programme Stockholm Convention of persistent organic pollutants http://www.pops.int/documents/convtext/convtext_en.pdf.
43. Lombardi V.C., Ruscetti F.W., Das Gupta J., et al. Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. Science 2009, 326:585-589.
44. Kermode-Scott B. Canada bans blood donations from people with history of chronic fatigue syndrome. BMJ 2010, 340:c1974.
45. Groom H.C., Boucherit V.C., Makinson K., et al. Absence of xenotropic murine leukaemia virus-related virus in UK patients with chronic fatigue syndrome. Retrovirology 2010, 7:1-10.
46. Alter H.J. Pathogen reduction: A precautionary principle paradigm. Transfus Med Rev 2008, 22:97-102.